"10.1371_journal.pone.0088739","plos one","2014-02-10T00:00:00Z","Stefan Hettwer; Shuo Lin; Stefan Kucsera; Monika Haubitz; Filippo Oliveri; Ruggero G Fariello; Markus A Ruegg; Jan W Vrijbloed","Neurotune AG, Schlieren, Zurich, Switzerland; Biozentrum, University of Basel, Basel, Switzerland","Conceived and designed the experiments: SH RGF MAR JWV. Performed the experiments: SH SL SK MH FO. Analyzed the data: SH SL SK MH FO MAR JWV. Contributed reagents/materials/analysis tools: SH SL SK MH FO. Wrote the paper: SH SL RGF MAR JWV.","The authors have the following interests. Stefan Hettwer, Stefan Kucsera, Monika Haubitz, Ruggero G. Fariello and Jan W. Vrijbloed are employed by Neurotune AG, and Stefan Hettwer, Ruggero G. Fariello and Jan W. Vrijbloed are shareholders of Neurotune. Neurotune is owned by shareholders and has interests to develop NT-1654 further to clinical applications. A patent application (PCT/EP2010/005372; US2012/0208765 A1) is pending with the title: Modified agrin fragment capable of restoring muscle strength for use as a medicament. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","02","Stefan Hettwer","SH",8,TRUE,4,5,7,5,TRUE,TRUE,FALSE,0,NA,FALSE
